CO2024007212A2 - Péptidos inmunogénicos magea1, proteínas de unión que reconocen péptidos inmunogénicos magea1, y usos de estos - Google Patents
Péptidos inmunogénicos magea1, proteínas de unión que reconocen péptidos inmunogénicos magea1, y usos de estosInfo
- Publication number
- CO2024007212A2 CO2024007212A2 CONC2024/0007212A CO2024007212A CO2024007212A2 CO 2024007212 A2 CO2024007212 A2 CO 2024007212A2 CO 2024007212 A CO2024007212 A CO 2024007212A CO 2024007212 A2 CO2024007212 A2 CO 2024007212A2
- Authority
- CO
- Colombia
- Prior art keywords
- magea1
- immunogenic peptides
- recognize
- binding proteins
- immunogenic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/876—Skin, melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163277924P | 2021-11-10 | 2021-11-10 | |
| US202263317337P | 2022-03-07 | 2022-03-07 | |
| US202263342415P | 2022-05-16 | 2022-05-16 | |
| PCT/US2022/049556 WO2023086480A2 (en) | 2021-11-10 | 2022-11-10 | Magea1 immunogenic peptides, binding proteins recognizing magea1 immunogenic peptides, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2024007212A2 true CO2024007212A2 (es) | 2024-09-09 |
Family
ID=86336428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2024/0007212A CO2024007212A2 (es) | 2021-11-10 | 2024-06-07 | Péptidos inmunogénicos magea1, proteínas de unión que reconocen péptidos inmunogénicos magea1, y usos de estos |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230270832A1 (https=) |
| EP (1) | EP4430067A2 (https=) |
| JP (1) | JP2024546018A (https=) |
| KR (1) | KR20240112285A (https=) |
| AU (2) | AU2022268347C1 (https=) |
| CA (1) | CA3237903A1 (https=) |
| CO (1) | CO2024007212A2 (https=) |
| IL (1) | IL312744A (https=) |
| MX (1) | MX2024005746A (https=) |
| TW (1) | TW202340224A (https=) |
| WO (1) | WO2023086480A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116716327B (zh) * | 2023-08-04 | 2023-10-20 | 科士华(南京)生物技术有限公司 | 一种构建tcr载体的方法 |
| TW202523702A (zh) * | 2023-10-27 | 2025-06-16 | 美商帝斯肯醫療公司 | Magea1免疫原性肽、識別magea1免疫原性肽之結合蛋白及其用途 |
| TWI871128B (zh) * | 2023-12-08 | 2025-01-21 | 陳乃銘 | 可準確提供循環腫瘤細胞（ｃｔｃ）所需藥物種類之方法 |
| WO2025217037A2 (en) * | 2024-04-08 | 2025-10-16 | Tscan Therapeutics, Inc. | Use of binding proteins for treatment of solid tumors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9340577B2 (en) * | 1992-08-07 | 2016-05-17 | Epimmune Inc. | HLA binding motifs and peptides and their uses |
| JPH09502086A (ja) * | 1993-08-06 | 1997-03-04 | サイテル コーポレイション | 完全ｍａｇｅ１遺伝子のクローニング及び特性決定 |
| WO2005115447A2 (en) * | 2004-05-25 | 2005-12-08 | The Trustees Of The University Of Pennsylvania | Human anti-cancer immunotherapy |
| WO2010037395A2 (en) * | 2008-10-01 | 2010-04-08 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
| AU2017252192C1 (en) * | 2016-04-19 | 2023-06-08 | Imcyse Sa | Novel immunogenic CD1d binding peptides |
| CN113795586B (zh) * | 2019-03-25 | 2026-03-27 | 大学健康网络 | T细胞受体及其使用方法 |
| WO2021119545A1 (en) * | 2019-12-11 | 2021-06-17 | Gritstone Bio, Inc. | Durable vaccination |
| US11464842B1 (en) * | 2021-04-28 | 2022-10-11 | Think Therapeutics, Inc. | Compositions and method for optimized peptide vaccines using residue optimization |
-
2022
- 2022-11-10 IL IL312744A patent/IL312744A/en unknown
- 2022-11-10 TW TW111143030A patent/TW202340224A/zh unknown
- 2022-11-10 CA CA3237903A patent/CA3237903A1/en active Pending
- 2022-11-10 MX MX2024005746A patent/MX2024005746A/es unknown
- 2022-11-10 US US17/984,647 patent/US20230270832A1/en active Pending
- 2022-11-10 WO PCT/US2022/049556 patent/WO2023086480A2/en not_active Ceased
- 2022-11-10 EP EP22893612.6A patent/EP4430067A2/en active Pending
- 2022-11-10 JP JP2024527417A patent/JP2024546018A/ja active Pending
- 2022-11-10 AU AU2022268347A patent/AU2022268347C1/en active Active
- 2022-11-10 KR KR1020247018764A patent/KR20240112285A/ko active Pending
-
2024
- 2024-01-26 AU AU2024200495A patent/AU2024200495A1/en active Pending
- 2024-06-07 CO CONC2024/0007212A patent/CO2024007212A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024005746A (es) | 2024-07-19 |
| CA3237903A1 (en) | 2023-05-19 |
| US20230270832A1 (en) | 2023-08-31 |
| AU2022268347C1 (en) | 2024-04-18 |
| EP4430067A2 (en) | 2024-09-18 |
| JP2024546018A (ja) | 2024-12-17 |
| AU2022268347A1 (en) | 2023-05-25 |
| WO2023086480A2 (en) | 2023-05-19 |
| TW202340224A (zh) | 2023-10-16 |
| WO2023086480A3 (en) | 2023-06-29 |
| AU2022268347B2 (en) | 2024-01-18 |
| KR20240112285A (ko) | 2024-07-18 |
| AU2024200495A1 (en) | 2024-02-15 |
| IL312744A (en) | 2024-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2024007212A2 (es) | Péptidos inmunogénicos magea1, proteínas de unión que reconocen péptidos inmunogénicos magea1, y usos de estos | |
| MX2020009568A (es) | Anticuerpos que se unen a cd39 y sus usos. | |
| CY1122494T1 (el) | Πρωτεϊνες συντηξης οι οποιες περιλαμβανουν μια πρωτεϊνη δεσμευσης και ενα πολυπεπτιδιο ιντερλευκινης-15 το οποιο εχει μια μειωμενη συγγενεια για il15ra και θεραπευτικες χρησεις αυτων | |
| CL2020000192A1 (es) | Anticuerpos anti-cd8 y usos de estos. | |
| UY39798A (es) | Anticuerpos anti-ccr8 y usos de los mismos | |
| CO2018010855A2 (es) | Nuevos anticuerpos anti-sirpa y sus aplicaciones terapéuticas | |
| MX420947B (es) | Constructos que reconocen específicamente glipicano 3 y usos de estos. | |
| BR112019018307A2 (pt) | Plataforma para identificação de peptídeos imunogênicos baseada em população | |
| CL2020003391A1 (es) | Proteína de unión al antígeno anti-steap1 | |
| CY1123781T1 (el) | Anti-tnf αλφα-αντισωματα και λειτουργικα θραυσματα αυτων | |
| EA201991168A1 (ru) | Белок, связывающий простатический специфический мембранный антиген | |
| JOP20170041B1 (ar) | اجسام مضادة ضد vista (b7h5) | |
| UY36304A (es) | Proteínas de fusión, bacterias recombinantes y métodos de uso de las bacterias recombinantes | |
| BR112016016737A2 (pt) | Peptídeos, dispositivos e métodos para detecção de anticorpos contra anaplasma | |
| EA201991876A1 (ru) | Антитела против фактора d и их применения | |
| CY1123784T1 (el) | Αντισωματα enanti-tnf αλφα και λειτουργικα θραυσματα αυτων | |
| MX2023005179A (es) | Proteínas de unión que reconocen antígeno ha-1 y usos de las mismas. | |
| CL2023000477A1 (es) | Proteínas de unión restringidas activadas de forma condicional | |
| BR112021026375A2 (pt) | Antígenos de câncer inovadores e métodos | |
| BR112022012731A2 (pt) | Anticorpo anti-ox40 e uso do mesmo | |
| CL2023002272A1 (es) | Anticuerpos y usos de estos | |
| CO2021010786A2 (es) | Toxinas apxia, apxiia y apxiiia inactivadas | |
| BR112023021162A2 (pt) | Peptídeos imunogênicos de magec2, proteínas de ligação que reconhecem os peptídeos imunogênicos de magec2 e usos dos mesmos | |
| CO2024007117A2 (es) | Proteínas de unión que reconocen al antígeno hpv16 e7 y usos de las mismas | |
| MX2023012111A (es) | Proteinas de union que reconocen el antigeno ha-2 y usos de estas. |